Hula, a Physical Activity Intervention for Female-Cancer Survivors

Browse trials for

• Ovarian Neoplasms 2,695
• Uterine Cervical Neoplasms 1,881
• Endometrial Neoplasms 1,325

Keywords

• hula
• breast cancer
• female
• hawaii
• physical activity
• cervical cancer
• ovarian cancer
• endometrial cancer

Ovarian Neoplasms

2,695 studies on the registry are indexed under Ovarian Neoplasms; 727 are open to participants now.

This study's enrollment of 73 is above the median of 60 across 2,030 interventional studies indexed under Ovarian Neoplasms.

Lead sponsor

University of Hawaii is the lead sponsor of 95 studies on the registry; 20 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 3 (43%) have results posted.

Study arms

• Other
  Hula

  Hula is an ancient, Native Hawaiian dance form of cultural expression and physical activity. Participants will attend one-hour hula classes twice a week for six months.

  Behavioral: Hula

Interventions

• BehavioralHula

Primary outcomes

1. Hula Program Feasibility (Compliance as measured by the proportion of total sessions attended and a questionnaire regarding satisfaction with the program at the end of the intervention)

   Compliance as measured by the proportion of total sessions attended and a questionnaire regarding satisfaction with the program at the end of the intervention

   Time frame: 6 months after the start of the intervention program

Secondary outcomes

1. Biomarkers - Sex Hormones (Circulating levels of sex hormones measured in serum samples)

   Circulating levels of sex hormones measured in serum samples.

   Time frame: Baseline, 6 months and 12 months after the start of the intervention program

2. Biomarkers - Cytokines (Circulating levels of cytokines measured in serum samples.)

   Circulating levels of cytokines measured in serum samples.

   Time frame: Baseline, 6 months and 12 months after the start of the intervention program

3. Biomarkers - Inflammatory Markers (Circulating levels of leptin, CRP, IGF-1, and IGFBP3 measured in serum samples collectively.)

   Circulating levels of leptin, CRP, IGF-1, and IGFBP3 measured in serum samples collectively.

   Time frame: Baseline, 6 months and 12 months after the start of the intervention program

4. DNA Methylation Patterns (DNA methylation patterns as detected with the Illumina Assay containing methylation sites in RefSeq genes and CpG islands collectively.)

   DNA methylation patterns as detected with the Illumina Assay containing methylation sites in RefSeq genes and CpG islands collectively.

   Time frame: Baseline, 6 months and 12 months after the start of the intervention program

5. Self-Report Outcomes - Demographics (Collectively looking at demographic items as measured on the baseline questionnaire, including ethnicity, education, family, history of cancer, stage of cancer, treatment type, and comorbidities.)

   Collectively looking at demographic items as measured on the baseline questionnaire, including ethnicity, education, family, history of cancer, stage of cancer, treatment type, and comorbidities.

   Time frame: Baseline, 6 months and 12 months after the start of the intervention program

6. Self-Report Outcomes - Physical Activity (Minutes per week of exercise assessed using The Women's Health Initiative Physical Activity Questionnaire)

   Minutes per week of exercise assessed using The Women's Health Initiative Physical Activity Questionnaire

   Time frame: Baseline, 6 months and 12 months after the start of the intervention program

7. Self-Report Outcomes - Health-Related Quality of Life (Quality of life of participants assessed using The European Organization for Research and Treatment of Cancer QLQ-C30.)

   Time frame: Baseline, 6 months and 12 months after the start of the intervention program

8. Self-Report Outcomes - Fatigue (assessed using The Brief Fatigue Inventory (BFI)

   The severity and impact of fatigue on daily functioning assessed using The Brief Fatigue Inventory (BFI).

   Time frame: Baseline, 6 months and 12 months after the start of the intervention program

9. Self-Report Outcomes - Depression (indicated using The Centers for Epidemiological Studies Depression Scale (CES-ED)

   The presence of depression as indicated using The Centers for Epidemiological Studies Depression Scale (CES-ED).

   Time frame: Baseline, 6 months and 12 months after the start of the intervention program

10. Self-Report Outcomes - Affective States (assessed using The Profile of Mood States short form (POMS-SF) questionnaire.)

    Affect of participants assessed using The Profile of Mood States short form (POMS-SF) questionnaire.

    Time frame: Baseline, 6 months and 12 months after the start of the intervention program

11. Self-Report Outcomes - Social Constraints (assessed using The 10-item Social Constraints Scale.)

    How people adjust and cope with a cancer diagnosis assessed using The 10-item Social Constraints Scale.

    Time frame: Baseline, 6 months and 12 months after the start of the intervention program

12. Self-Report Outcomes - Cognitive Functioning (assessed using the 42-item FACTcog

    2 subscales assess cognitive deficiency and cognitive capability

    Time frame: Baseline, 6 months and 12 months after the start of the intervention program

Individual participant data

Plan to share: No